Abstract
Viral Hepatitis B is the cause of significant disease worldwide. Acute infection occurs with hepatitis B, but chronic asymptomatic infection leading to chronic liver disease and hepatocellular carcinoma is a life long concern.
The natural history of hepatitis B (HBV) is well established in adults, but the long-term outcome for children is unclear. The main mechanism of infection in childhood is perinatal transmission, which can be prevented effectively by vaccination.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bortolotti, F., Jara, P., Barbera, C., Gregorio, G.V., Veggente, A., Zancan, L., Hierro, L. et al. (2000). Long term effect of alpha interferon in children with chronic hepatitis B. Gut, 46(5), 715–718.
Bortolotti, F., Jara, P., Crivello, C., Hierro, L., Cadrobbi, P., Frauca, E., Camarena, C. et al. (1998). Outcome of chronic hepatitis B in caucasian children during a 20-year observation period. J Hepatol, (29), 184–190.
Boxall, E.H., Sira, J., Ballard, A.L., Davies, P., & Kelly, D.A. (2006). Long term follow up of hepatitis B carrier children treated with interferon and prednisolone. J Med Virol, (78), 888–895.
Boxall, E.H., Sira, J., El-Shukri, N., Kelly, D.A. (2004a). Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis, 190(7), 1264–1269.
Boxall, E.H., Sira, J., Standish, R.A., Davies, P., Sleight, E., Dhillon, A.P. et al. (2004b). Natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed, 89(5), 456–460.
Chu, C.M. (2000). Natural history of chronic hepatitis B virus infection in adults, emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol, 15(Suppl), E25–E30.
D’Antiga, L., Aw, M., Atkins, M. et al. (2006). Combined lamivudine/interferon alfa treatment in immune tolerant children perinatally infected with Hepatitis B; a pilot study. J Pediatr, (148), 228–233.
European Association for the Study. (2009). EASL clinical practice guidelines: management of hepatitis B. J Hepatol, 50(2), 227–242.
Ghany, M. & Liang, T.J. (2007). Drug targets and molecular mechanisms of drug resistance in chronic Hepatitis B. Gastroenterology, (132), 1574–1585.
Hadziyannis, S., Tassopoulos, N.C., Heathcote, E.J., Chang, T.T., Kitis, G., Rizzetto, M. et al. Adefovir Dipivoxil 438 Study Group. (2005). Long-term therapy with Adefovir Dipivoxil 438 Study Group. N Engl J Med, (352), 2673–2681.
Jara, P., & Bortolotti, F. (1999). Interferon-α treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr, (29), 163–170.
Jonas, M., Kelly, D., & Mizerski, J. (2002). Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J, (346), 1706–1713.
Jonas, M.M., Kelly, D., Pollack, H., Mizerski, J., Sorbel, J., Frederick, D. et al. (2008). Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology, 47(6), 1863–1871.
Lai, C.L., Leung, N., Teo, E.K. et al. (2005). A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology, (129), 528–536.
Lau, G.K., Piratvisuth, T., Luo, K.X. et al. (2005). Peginterferon Alfa2a, lamivudine, and the combination for HBeAG-positive chronic hepatitis B. N Engl J Med, (352), 2682–2695.
Lavanchy, D. (2004). Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Viral Hepat, (11), 97–107.
Lee, W.S., McKiernan, P., & Kelly, D.A. (2005). Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom. JPGN, (40), 575–581.
Lok, A.S. & McMahon, B.J. (2007). Chronic hepatitis B. Hepatology, (45), 507–539.
Moore, S.W., Millar, A.J., Hadley, G.P., Ionescu, G., Kruger, M., Poole, J. et al. (2004). Hepatocellular carcinoma and liver tumors in South African children: a case for increased prevalence. Cancer, 101(3), 642–649.
Perillo, R., Schiff, E., Magill, A., & Murray, A. (1999) In vivo demonstration of sensitivity of YMDD variants to adefovir. Gastroenterol, (116), A1261.
Petersen, K.M., Bulkow, L.R., McMahon, M.D., Zanis, C., Getty, M., Peters, H., & Parkinson, A.J. (2004). Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J, (23), 650–655.
Rehermann, B. (2003). Immune responses in hepatitis B virus infection. Semin Liver Dis, (23), 21–38.
Sherman, M., Yurdaydin, C., Sollano, J., Liaw, Y.F. et al. (2006). Entecavir for treatment of lamivudine-refractory HbeAg-positive chronic hepatitis B. Gastroenterology, 130(7), 2039–2049.
Sokal, E.M., Kelly, D.A., Mizerski, J., Badia, I.B., Areias, J.A., Schwarz, K.B. et al. (2006). Long term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology, 43(2), 225–232.
Terrault, N.A. (2002). Treatment of recurrent hepatitis B infection in liver transplant recipients. Liver Trans, 8(Suppl 10), S74–S81.
van Bommel, F., Zollner, B., Sarrazin, C. et al. (2006). Tenofovir for patients with lamivudine-resistance hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology, 44(2), 318–325.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Kelly, D. (2010). Current Status of Treatment of Hepatitis B in Children. In: Finn, A., Curtis, N., Pollard, A. (eds) Hot Topics in Infection and Immunity in Children VI. Advances in Experimental Medicine and Biology, vol 659. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0981-7_10
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0981-7_10
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-0980-0
Online ISBN: 978-1-4419-0981-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)